2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOCompleted
Primary Objective: To establish a prediction model for the probability of vaginal delivery and successful vacuum extraction at the second stage of labor, using the angle of progression by transperineal ultrasound. Secondary Objective(s): To evaluate…